Research Trials

Check out the list below of some current clinical trials recruiting across Canada. If you are interested in participating in a clinical trial, click here and you will be prompted to create an account for Cambian Navigator. Navigator is an online system that will send you notifications of research opportunities that you may qualify for. If you are a researcher and would like your trial listed, please contact Alicia at amurdoch@cansolveckd.ca.

Current Research Trials Looking For Participants:

AdDIT
Adolescent Type I Diabetes Cardio-Renal Intervention Trial

This project is studying an observational group of youth with type 1 diabetes along with a group of healthy age-matched subjects and following them long term by assessing both kidney and cardiovascular function. The study team is measuring biological, psychosocial and social factors to identify and better understand who is at risk for the development of chronic kidney disease. 

De-prescribing
Targeted de-prescribing in patients with chronic kidney disease to decrease polypharmacy

Patients on hemodialysis take 12 medications per day on average. Many of these medications lack high-quality evidence to show their effectiveness and safety in HD patients. This project will develop tools to help reduce the use of medications that lack evidence for effectiveness and safety in hemodialysis patients.

iCARE
Improving renal complications in adolescents with type 2 diabetes through research

This project is measuring biological, psychological and social factors in youth, as well as blood biomarkers (markers of inflammation, proteins, hormones and kidney filter micro-particles) that could both contribute to the risk of CKD, as well as signal high-risk patients that need more intensive treatment. This will potentially lead to a better understanding of why kidney injury happens in youth with diabetes, and what can potentially be done to stop or slow down this process in order to decrease the risk of kidney failure in adulthood.

Interested in Seeing More Research Trials?

Visit ClinicalTrials.gov's Database

View More
Kidney Check
Optimal Approaches to Chronic Kidney Disease Case Finding in Indigenous Communities

Using mobile lab equipment, screening teams will travel to communities and test for CKD and its risk factors, including diabetes and high blood pressure. This information will be used to determine an individual’s risk of CKD, and each person will receive a treatment plan that is tailored to their risk.

Triple I
Priorities for improving information, interaction, and individualization among patients on hemodialysis

This project aims to collect information on opportunities for change in models of care for patients undergoing hemodialysis with a goal to improve patient healthcare experience.

We are looking for volunteers with lived hemodialysis experience to participate in an anonymous survey. We are conducting this survey to improve our understanding of what people receiving in-centre hemodialysis (HD) need and want from their health providers People on in-centre HD, family members and caregivers of people on in-centre HD, and health care providers in HD are eligible.


ACHIEVE
Aldosterone inhibition and enhanced toxin removal in hemodialysis patients

Forty percent of patients that require dialysis die within three years, mostly due to heart disease. Spironolactone is a drug that is very effective at reducing scarring of the heart and might help prevent heart-related deaths in patients with kidney failure. This study aims to determine if spironolactone reduces heart related deaths and hospitalizations due to heart failure.

Drs Michael Walsh and David Collister are leading this large international study with over 5,000 dialysis patients in several countries. Patients will be randomly assigned to spironolactone or a placebo pill that looks and tastes just like spironolactone but does not have any spironolactone in it. Patients will be followed for about five years in order to determine how often heart problems occurs in patients who take spironolactone compared to those that take the placebo. Another objective of the study is to determine whether the spironolactone changes patient’s quality of life or the degree to which they feel unwell or washed out after dialysis. 

Canadian Glomerulonephritis Registry
Canadian Glomerulonephritis Registry

Dr. Heather Reich is leading this project to create a network to develop personalized treatments for patients with Glomerulonephritis (GN) and identify new ways of detecting high-risk GN. To do this, the research team will build upon an established research program to develop a collaborative national patient-centred program. They will expand a successful clinical database structure, so it is available to the Canadian research community. The research team will study strategies for GN treatment that are tailored to a patient’s individual needs and will look for specific genes and proteins that can help predict disease progression and whether an individual will benefit from innovative treatments. Patients enrolled in our study will be seen every six months for blood tests and updates regarding their health and well-being.